Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective
- Submitting institution
-
The University of Sheffield
- Unit of assessment
- 2 - Public Health, Health Services and Primary Care
- Output identifier
- 383
- Type
- D - Journal article
- DOI
-
10.1080/13696998.2018.1457533
- Title of journal
- Journal of Medical Economics
- Article number
- -
- First page
- 666
- Volume
- 21
- Issue
- 7
- ISSN
- 1369-6998
- Open access status
- Compliant
- Month of publication
- April
- Year of publication
- 2018
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
9
- Research group(s)
-
E - Health Technology Assessment
- Citation count
- 15
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -
